Mitchell Krassan Net Worth

The estimated Net Worth of Mitchell Krassan is at least $1.58 Million dollars as of 3 February 2020. Mr. Krassan owns over 300,000 units of TherapeuticsMD Inc stock worth over $533,370 and over the last 11 years he sold TXMD stock worth over $0. In addition, he makes $1,044,990 as Chief Strategy and Performance Officer at TherapeuticsMD Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Krassan TXMD stock SEC Form 4 insiders trading

Mitchell has made over 11 trades of the TherapeuticsMD Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 300,000 units of TXMD stock worth $60,000 on 3 February 2020.

The largest trade he's ever made was exercising 300,000 units of TherapeuticsMD Inc stock on 3 February 2020 worth over $60,000. On average, Mitchell trades about 21,875 units every 92 days since 2014. As of 3 February 2020 he still owns at least 300,000 units of TherapeuticsMD Inc stock.

You can see the complete history of Mr. Krassan stock trades at the bottom of the page.

Mitchell Krassan biography

Mitchell L. Krassan CPA serves as Chief Strategy and Performance Officer of the Company. From April 2010 to October 2011, Mr. Krassan served as Chief Strategy and Performance Officer of VitaMed. From September 2010 to June 2011, Mr. Krassan serves as our Chief Financial Officer. Mr. Krassan was a partner with EquiMark Limited, a private investment partnership, from 1997 to 2010. From November 1994 to July 1997, Mr. Krassan served as Chief Financial Officer and Chief Operating Officer of The Reich Group/Telespectrum Worldwide, a fully integrated direct marketing firm that provided clients expertise in market research and analysis, strategic planning, marketing, creative, and production services, telemarketing and database development. Mr. Krassan earned a B.S. in Accounting from the University of Maryland, received his certification as a CPA in the state of Maryland, and earned his M.B.A. in Management from New York University.

What is the salary of Mitchell Krassan?

As the Chief Strategy and Performance Officer of TherapeuticsMD Inc, the total compensation of Mitchell Krassan at TherapeuticsMD Inc is $1,044,990. There are 4 executives at TherapeuticsMD Inc getting paid more, with John Milligan having the highest compensation of $1,440,640.

How old is Mitchell Krassan?

Mitchell Krassan is 54, he's been the Chief Strategy and Performance Officer of TherapeuticsMD Inc since 2018. There are 11 older and 15 younger executives at TherapeuticsMD Inc. The oldest executive at TherapeuticsMD Inc is Tommy Thompson, 78, who is the Independent Chairman of the Board.

What's Mitchell Krassan's mailing address?

Mitchell's mailing address filed with the SEC is 951 YAMATO ROAD, SUITE 220, BOCA RATON, FL, 33431.

Insiders trading at TherapeuticsMD Inc

Over the last 13 years, insiders at TherapeuticsMD Inc have traded over $21,656,853 worth of TherapeuticsMD Inc stock and bought 721,732 units worth $2,299,099 . The most active insiders traders include Cooper C. Collins, Brian Bernick, and Robert G Finizio. On average, TherapeuticsMD Inc executives and independent directors trade stock every 29 days with the average trade being worth of $272,607. The most recent stock trade was executed by John C.K. Iv Milligan on 25 October 2019, trading 72,000 units of TXMD stock currently worth $198,000.

What does TherapeuticsMD Inc do?

therapeuticsmd, inc. is an innovative pharmaceutical company exclusively committed to advancing the health of women and championing awareness of their health care issues. we create products to address the unique changes and challenges women experience through every stage of their lives. with momentum fueled by the needs of our customers, we combine entrepreneurial spirit and clinical expertise to develop innovative solutions designed to go beyond what is presently available. this includes a variety of therapies in our pipeline, along with prescription prenatal vitamins under the vitamedmd® and bocagreenmd® brands. see our community guidelines: https://www.therapeuticsmd.com/social-media-community-guidelines

Complete history of Mr. Krassan stock trades at TherapeuticsMD and TherapeuticsMD Inc

TherapeuticsMD Inc executives and stock owners

TherapeuticsMD Inc executives and other stock owners filed with the SEC include:

• John Milligan,
  President, Secretary
• Brian Bernick,
  Co-Founder
• Robert Finizio,
  Chief Executive Officer and Director
• Robert G. Finizio,
  Co-Founder & Vice Chair
• Mitchell Krassan,
  Chief Strategy and Performance Officer
• John C. K. Milligan IV,
  Chief Exec. Officer of VitaCare Prescription Services
• Michael Donegan,
  Vice President - Finance
• Tommy Thompson,
  Independent Chairman of the Board
• Cooper Collins,
  Independent Director
• J. Martin Carroll,
  Independent Director
• Angus Russell,
  Independent Director
• Jules Musing,
  Independent Director
• Dr. Brian A. Bernick,
  Co-Founder & Chief Scientific Officer
• Nichol Ochsner,
  Vice President, Investor Relations
• Gail Naughton,
  Independent Director
• Karen Ling,
  Independent Director
• Paul Bisaro,
  Independent Director
• Bharat Warrier,
  Chief Manufacturing Officer
• Sebastian Mirkin,
  Chief Medical Officer
• Dawn Halkuff,
  Chief Commercial Officer
• Marlan Walker,
  General Counsel
• John Knighton,
  Chief Compliance Officer
• Adam Miller,
  Chief Information Officer
• James D'Arecca,
  Chief Financial Officer
• Julia M. Amadio,
  Chief Product Officer
• Mitchell L. Krassan,
  Exec. VP and Chief Strategy & Performance Officer
• Chris Gish,
  Sr. VP of Sales
• Michael Donegan,
  Chief Accounting Officer & VP of Fin.
• James C. D'Arecca,
  Chief Financial Officer
• Hugh O'Dowd M.B.A.,
  Pres, CEO & Director
• Robert V Jr La Penta,
  Director
• Nicholas Segal,
  Director
• Jane F Barlow,
  Director
• Daniel A Cartwright,
  Chief Financial Officer
• Randall S Stanicky,
  Director
• Samuel A Greco,
  Director